Evaluation of the clinical efficacy and safety of the combined administration of Imidafenacin and alfa1-blocker in BPH patients with OAB.
- Conditions
- Overactive bladder
- Registration Number
- JPRN-UMIN000007973
- Lead Sponsor
- FUN(Fukuoka Urology Network)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Male
- Target Recruitment
- 100
Not provided
1)Patients who have administered prohibited substances or done prohibited therapy within the 4 weeks before enrollment. (Sex hormone drug and 5-alpha reductase inhibitor within the 52 weeks before enrollment.) 2)Patients who changed the dosage or usage of a restricted medicine within the 4 weeks before enrollment 3)Patients with prostate cancer, neurogenic bladder, urethra stricture, chronic prostatitis, symptomatic urinary tract infection, urinary tract stones and interstitial cystitis 4)Patients with anuresis 5)Patients with pyloristenosis, constriction of dodecadactylon, construction of enteron and adynamic ileus 6)Patients with deterioration of enterokinesis 7)Patients with angle-closure glaucoma 8)Patients with myasthenia gravis 9)Patients with serious cardiac disorder, serious liver dysfunction and serious kidney dysfunction 10)Patients with history of hypersensitive reaction to anticholinergic agents 11)Residual urine volume is more than 50mL 12)Patients in which it has been confirmed that Qmax is less than 5mL/s 13)Patients with Polyuria 14)Any other patients who are regarded as unsuitable for this study by the investigator
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method